Most experts who develop cancer treatment guidelines have ties to industry
(By Ed Silverman for STAT) As cancer treatments become both more innovative and costlier, a new study finds that most
Read More
Part D/Prescription Drugs
Under fire, Mylan takes steps to make $600 EpiPen more affordable
(Ed Silverman for STAT) In the face of withering criticism, Mylan Pharmaceuticals took steps Thursday to make its EpiPen device more affordable. Specifically, the
Read MoreGovernment-Protected ‘Monopolies’ Drive Drug Prices Higher, Study Says
(By Sydney Lupkin for Kaiser Health News) The “most important factor” that drives prescription drug prices higher in the United
Read MoreHow Obama’s FDA keeps generic drugs off the market
(By Scott Gottlieb, MD for AEI) One of the biggest factors fueling the angst over drug prices in the U.S.
Read MoreExperimental cancer therapy holds great promise — but at great cost
(by Meghana Keshavan for STAT) Soon after she received the treatment, Karen Koehler’s brain swelled. Her blood pressure plummeted. As
Read MoreSenators press Mylan Labs over ‘outrageous’ EpiPen pricing
(By Ed Silverman for STAT) Move over, Martin Shkreli. Get in line, Valeant Pharmaceuticals. Congress appears to have found another
Read MoreMany clinical trials’ findings never get published. Here’s why that’s bad
(By Ivan Oransky and Adam Marcus for STAT) When a bearded dude at a Brooklyn coffee house says he’s shopping
Read MoreThis is your brain on pot: Neuroscientist studies long-term effects of medical marijuana
(By Leah Samuel for STAT) BELMONT, Mass. — Staci Gruber vividly remembers her first hit of marijuana, back when she
Read MoreGetting Better Data on Which Drugs Are Killing People
(By Christine Vestal for The PEW Charitable Trust) AUBURN, Ala. — As the opioid epidemic surges, Alabama’s toxicologists are testing
Read MoreDo incentives nudge physicians to prescribe opioids for pain?
(By Dhruv Khullar and Anupam Jena for STAT) Humans have used opioids to treat pain, both physical and mental, for
Read More